Search - tctmd.com

Displaying 21 - 22 of 22

Sort: Relevancy | Date

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.